Tapering and withdrawing opioids: guidance informed by fundamental principles to minimise withdrawal symptoms
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index; 70 of the 133 sources its claims cite were checked for support.
Abstract
Formal guidelines recommend that opioids should be stopped when risks outweigh benefits. These guidelines generally recommend gradual dose tapering at a rate tolerable to the patient. We examined the pharmacodynamic properties of opioids to derive pharmacologically rational principles for tapering. As dictated by the law of mass action, the relationship between dose of opioid and effect on its principal target, the mu-opioid receptor, is hyperbolic, with diminishing incremental effects for increasing doses. This suggests that in order to mitigate withdrawal symptoms, opioid doses should be tapered according to a corresponding hyperbolic pattern, with dose reductions becoming increasingly small as total dose reduces. This can be approximated by proportional decreases (e.g. 1%–10% reduction of the most recent dose every 1–2 weeks). Dose reductions should be titrated to withdrawal symptoms throughout the process, and final doses before complete cessation will need to be very small (such as 0.1 mg of buprenorphine or 1 mg of methadone, or less).
Overview
CoChat Summary
## TL;DR
This paper argues that opioid tapers should generally follow a hyperbolic pattern, not a linear one, because the dose–mu-opioid receptor relationship is hyperbolic and linear tapers can cause disproportionately large receptor changes at low doses. The authors propose proportional reductions of the most recent dose, with very small final doses and adjustments based on withdrawal symptoms.
## Key findings
- The paper reports that opioid effects on the mu-opioid receptor (MOR) are hyperbolic, with diminishing incremental effects at higher doses, so tapering should also be hyperbolic to produce more even reductions in receptor occupancy.
- In buprenorphine data from Greenwald et al. measured 4 h after 12 days of maintenance treatment at 1–32 mg, reducing by 4 mg from 16 mg caused a 5.2 percentage-point drop in MOR activity, whereas reducing by 4 mg from 4 mg to 0 mg caused a 53.9 percentage-point drop.
- The abstract recommends proportional dose reductions of about 1%–10% of the most recent dose every 1–2 weeks, with final doses before cessation possibly as low as 0.1 mg of buprenorphine or 1 mg of methadone, or less.
- Cited observational evidence suggests slower tapers do better: tapers of 12–52 weeks were 3.6 times more likely to succeed and tapers >52 weeks were 6.7 times more likely to succeed than tapers <12 weeks; another study found <5%/week doubling the chance of stopping opioids versus 5%–10%/week, and <5 mg methadone/week gave a 5-fold increased chance of a positive outcome versus >10 mg/week.
## Methods
- This is a conceptual/narrative review that uses pharmacodynamic principles, especially the law of mass action, to derive tapering schedules.
- The authors searched published studies via Google Scholar on MOR occupancy measured by PET in clinical subjects and on relationships between occupancy and clinical effects, including withdrawal; they state there was a single buprenorphine occupancy study used for dose-reduction calculations.
- They also briefly reviewed evidence on taper duration, adjunctive medications, and nonpharmacological aspects of stopping opioids.
## Limitations
- The paper states that individual pharmacodynamic and pharmacokinetic differences mean average-based taper regimens should be used cautiously, and withdrawal symptoms should guide the pace for each patient.
- It states that much of the tapering logic is based on approximations: receptor-occupancy data were measured 4 h post-dose rather than at peak or trough, and for most opioids there are no primary MOR-occupancy data, so regimens are extrapolated from buprenorphine or dose conversions.
- The text makes evident that the paper is not an empirical trial of the proposed tapering schedules, but a theory- and evidence-informed proposal; the authors explicitly call for randomized controlled trials.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
47 Valid · 14 Not valid · 42 Not checked · 36 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The pivotal importance of the MOR in the effect of opioids is borne out by studies that find that opioid agonist effects are linearly related to occupancy of this receptor. 18”
§ Tapering and withdrawing opioids: guidance informed by fundamental principles to minimise withdrawal symptoms > Results > Neurobiology of opioid tapering
What the sources say
- Disputedcites [18] Greenwald MK Comer SD Fiellin DA. Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy. Drug Alcohol Dependence 2014; 144(2): 1– 11. 25179217 PMC4252738 sourceExperimental — accuracy not yet measured
The Results (section 3; page not provided) relate μ-opioid receptor availability to pharmacodynamic responses using non-linear regression curves, contrary to the claimed linear relationship. The Methods (section 2.1; page not provided) also caution that receptor availability is an indirect measure and that calling it occupancy can be misleading. (LLM, conf=0.86)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In another analysis, only 13.7% of patients tapering opioids achieved complete cessation in a 9-year window. 43”
§ Tapering and withdrawing opioids: guidance informed by fundamental principles to minimise withdrawal symptoms > Results > Gradual tapers versus shorter tapers
What the sources say
- Disputedcites [43] Fenton JJ Agnoli AL Xing G, et al. Trends and rapidity of dose tapering among patients prescribed long-term opioid therapy, 2008-2017. JAMA Network Open 2019; 2(11): e1916271. PMC6902834 31730189 sourceExperimental — accuracy not yet measured
The Results report that 13.7% was the percentage of patients tapering their daily opioid dose in 2015, not the percentage of tapering patients who stopped opioids. The Methods define tapering as a dose reduction of at least 15% during a seven-month follow-up, and the Limitations say the study did not evaluate whether reductions were sustained. No cessation rate over a nine-year window is reported in these passages. (LLM, conf=0.89)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“There is also consensus on the observation that the time taken for patients to taper off opioids is highly variable, with some patients requiring months or years to successfully stop opioids, especially when use has been prolonged.5,13”
§ Tapering and withdrawing opioids: guidance informed by fundamental principles to minimise withdrawal symptoms > Introduction > Approaches to tapering opioids
What the sources say
- Not matchedcites [5] Dowell D. HHS Guide for clinicians on the appropriate dosage reduction or discontinuation of long-term opioid analgesics. Washington, DC: The US Department of Health and Human Services Working Group on Patient-Centered Reduction or Discontinuation of Long-term Opioid Analgesics. 2019, pp. 1– 6. PMC7145754 31600366
We don’t have this paper’s reference list.
- Supportedcites [13] Dowell D Haegerich T Chou R. No shortcuts to safer opioid prescribing. N Engl J Med 2019; 380(24): 2285– 2287. 31018066 PMC6573011 source
In “No Shortcuts to Safer Opioid Prescribing” (page not provided), the authors say tapering pace may be individualized, patients exposed to high dosages for years may need slower tapers, and success might require months to years. This supports the claim that tapering time varies, particularly after prolonged use. (LLM, conf=0.92)
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“There is also consensus on the observation that the time taken for patients to taper off opioids is highly variable, with some patients requiring months or years to successfully stop opioids, especially when use has been prolonged.5,13”
§ Tapering and withdrawing opioids: guidance informed by fundamental principles to minimise withdrawal symptoms > Introduction > Approaches to tapering opioids
What the sources say
- Not matchedcites [5] Dowell D. HHS Guide for clinicians on the appropriate dosage reduction or discontinuation of long-term opioid analgesics. Washington, DC: The US Department of Health and Human Services Working Group on Patient-Centered Reduction or Discontinuation of Long-term Opioid Analgesics. 2019, pp. 1– 6. PMC7145754 31600366
We don’t have this paper’s reference list.
- Supportedcites [13] Dowell D Haegerich T Chou R. No shortcuts to safer opioid prescribing. N Engl J Med 2019; 380(24): 2285– 2287. 31018066 PMC6573011 source
In “No Shortcuts to Safer Opioid Prescribing” (page not provided), the authors say patients exposed to high opioid dosages for years may need slower, individualized tapers and that success might require months to years. This supports the attributed claim. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This hyperbolic relationship is dictated by the law of mass action, where initial doses have the greatest effect but each additional gram of a drug has less and less effect as receptors become saturated. 32”
§ Tapering and withdrawing opioids: guidance informed by fundamental principles to minimise withdrawal symptoms > Results > Neurobiology of opioid tapering
What the sources say
- Partly supportedcites [32] Holford N. Pharmacodynamic principles and the time course of delayed and cumulative drug effects. Transl Clin Pharmacol 2018; 26(2): 56. 32055549 PMC6989261 sourceExperimental — accuracy not yet measured
In “Cumulative drug responses” (page unavailable), the paper reports that 40 mg of furosemide produces nearly as large a maximum effect as 120 mg, supporting diminishing gains as effect approaches a maximum. “Binding to Receptor” discusses equilibrium binding, but the copy does not attribute a hyperbolic dose–occupancy relationship to the law of mass action or establish that each additional gram has progressively less effect for drugs generally. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
72 more claims · 35 with their cited sources checked
Create a free account to see all 139 claims and every source verdict.
- It may state two separate claims as one. 44
- Probably not a substantial claim. 29
Citations
Cites
CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016
Dowell, D., Haegerich, T. M., & Chou, R. (2016) · JAMA · doi:10.1001/jama.2016.1464 · Cited by 5,161
Chou, R., Turner, J. A., Devine, E. B., Hansen, R. N., Sullivan, S. D., Blazina, I., Dana, T., Bougatsos, C., & Deyo, R. A. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2559 · Cited by 1,606
A Comparison of Levomethadyl Acetate, Buprenorphine, and Methadone for Opioid Dependence
Johnson, R. E., Chutuape, M. A., Strain, E. C., Walsh, S. L., Stitzer, M. L., & Bigelow, G. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011023431802 · Cited by 623
Eap, C. B., Buclin, T., & Baumann, P. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241140-00003 · Cited by 599 · cited 1×
“Additionally, the elimination half-lives of opioids can relate to both genetic (e.g. variations in CYP P450 iso-enzymes) and nongenetic factors (such as other interactions with other medications or substances), 50 and this can influence withdrawal effects.”
REVIEW: Acute withdrawal, protracted abstinence and negative affect in alcoholism: are they linked?
Heilig, M., Egli, M., Crabbe, J. C., & Becker, H. C. (2010) · Addiction Biology · doi:10.1111/j.1369-1600.2009.00194.x · Cited by 435 · cited 2×
“2,21,46,47 As withdrawal symptoms are thought to be produced by the mismatch between the raised homeostatic set-point of the mu-opioid system following long-term opioid dependence and levels of opioid agonism produced by medication, 48 these periods of time likely reflect the time period required…”
No Shortcuts to Safer Opioid Prescribing
Dowell, D., Haegerich, T., & Chou, R. (2019) · New England Journal of Medicine · doi:10.1056/nejmp1904190 · Cited by 408
Greenwald, M. K., Johanson, C.-E., Moody, D. E., Woods, J. H., Kilbourn, M. R., Koeppe, R. A., Schuster, C. R., & Zubieta, J.-K. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300251 · Cited by 320 · cited 2×
“There was a single study by Greenwald et al. 17 (as reported in Greenwald et al. 18 ) that reported occupancy data for mu-opioid occupancy for buprenorphine.”
Frank, J. W., Lovejoy, T. I., Becker, W. C., Morasco, B. J., Koenig, C. J., Hoffecker, L., Dischinger, H. R., Dobscha, S. K., & Krebs, E. E. (2017) · Annals of Internal Medicine · doi:10.7326/m17-0598 · Cited by 318 · cited 1×
“44 Gradual tapers generally have better outcomes than shorter tapers.”
Tapering of SSRI treatment to mitigate withdrawal symptoms
Horowitz, M. A., & Taylor, D. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30032-x · Cited by 280
Self-citationYáñez, J. A., Remsberg, C. M., Sayre, C. L., Forrest, M. L., & Davies, N. M. (2011) · Therapeutic Delivery · doi:10.4155/tde.11.19 · Cited by 279 · cited 1×
“…by use of the very long-acting buprenorphine implant (Sixmo), 70 which exhibits flip-flop pharmacokinetics (where the absorption half-life predominates over the elimination half-life to determine duration of drug action) 71 and might allow gradual tapering by reducing the number of implants used.”
Neural Systems Underlying Opiate Addiction
De Vries, T. J., & Shippenberg, T. S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-09-03321.2002 · Cited by 270 · cited 3×
“19,20 Withdrawal symptoms occur when opioids are reduced or stopped because the raised homeostatic set-point of the mu-opioid system registers reduced doses as ‘under activation’.”
Discontinuation of Buprenorphine Maintenance Therapy: Perspectives and Outcomes
Bentzley, B. S., Barth, K. S., Back, S. E., & Book, S. W. (2015) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2014.12.011 · Cited by 176 · cited 2×
“36 Both opioids examined here have relatively long plasma elimination half-lives (37 h for buprenorphine and 29 h for methadone) 16 which can facilitate gradual tapers, especially as these plasma half-lives may be shorter than receptor binding half-lives.”
Greenwald, M. K., Comer, S. D., & Fiellin, D. A. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.07.035 · Cited by 174 · cited 4×
“There was a single study by Greenwald et al. 17 (as reported in Greenwald et al. 18 ) that reported occupancy data for mu-opioid occupancy for buprenorphine.”
InfluentialProtracted withdrawal syndromes from benzodiazepines
Ashton, H. (1991) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(91)90023-4 · Cited by 170
A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse
Horowitz, M. A., Jauhar, S., Natesan, S., Murray, R. M., & Taylor, D. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab017 · Cited by 157
Self-citationOpioid Treatments for Chronic Pain
Chou, R., Hartung, D., Turner, J., Blazina, I., Chan, B., Levander, X., McDonagh, M., Selph, S., Fu, R., & Pappas, M. (2020) · doi:10.23970/ahrqepccer229 · Cited by 152
Neurobiology of opioid dependence in creating addiction vulnerability
Evans, C. J., & Cahill, C. M. (2016) · F1000Research · doi:10.12688/f1000research.8369.1 · Cited by 146 · cited 8×
“…tolerance occurs because of the drive to homeostatic balance, 2 involving de-sensitisation and down-regulation of MORs, as well as modifications to the mu-signalosome, neuronal proteome, transcriptome and neuronal morphology, 20 with consequent downstream effects on mesolimbic dopaminergic neurons.”
InfluentialTreating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option
Davis, M. P., Pasternak, G., & Behm, B. (2018) · Drugs · doi:10.1007/s40265-018-0953-z · Cited by 138 · cited 1×
“In the US, the smallest available dose for sublingual buprenorphine is 2 mg, but buccal film is available in as small as a dose of 75 ug, equivalent to 150 ug of sublingual buprenorphine, 62 potentially facilitating some of the regimens out-lined here.”
Analgesic efficacy of opioids in chronic pain: recent meta‐analyses
Reinecke, H., Weber, C., Lange, K., Simon, M., Stein, C., & Sorgatz, H. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12634 · Cited by 120 · cited 1×
“However, a hyperbolic, gradual taper is likely to For those patients prescribed for pain the underlying pain disorder may present difficulties, despite it being now clear that opioids are largely ineffective for chronic non-cancer pain 53 and can even make pain worse.”
Kling, M. A., Carson, R. E., Borg, L., Zametkin, A., Matochik, J. A., Schluger, J., Herscovitch, P., Rice, K. C., Ho, A., Eckelman, W. C., et al. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39007-x · Cited by 119 · cited 1×
“38,39 This has been attributed to either the insensitivity of the radi-otracers used, or to their inability to label receptors internalised by methadone agonism.”
Withdrawal From Methadone Maintenance: Rate of Withdrawal and Expectation
Senay, E. C. (1977) · Archives of General Psychiatry · doi:10.1001/archpsyc.1977.01770150119014 · Cited by 117 · cited 6×
“35 Patients who are provided with maintenance treatment but blinded (so they do not know whether they are reducing or maintaining) show drop-out rates almost as high as those who are gradually withdrawing from medication, 35 suggesting that expectations of withdrawal (nocebo effects) may contribute…”
InfluentialHedonic homeostatic dysregulation as a driver of drug-seeking behavior
Koob, G. F. (2008) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2009.04.002 · Cited by 114 · cited 1×
“52 Addressing these issues are beyond the scope of this paper, which has mainly focused on people with physical dependence to opioids.”
The Conundrum of Opioid Tapering in Long-Term Opioid Therapy for Chronic Pain: A Commentary
Manhapra, A., Arias, A. J., & Ballantyne, J. C. (2018) · Substance Abuse · doi:10.1080/08897077.2017.1381663 · Cited by 98 · cited 5×
“2,20 This concept is supported by the ability of MOR antagonists to induce withdrawal symptoms in individuals with physiological opioid dependence.”
InfluentialDowell, D., Compton, W. M., & Giroir, B. P. (2019) · JAMA · doi:10.1001/jama.2019.16409 · Cited by 98
Trends and Rapidity of Dose Tapering Among Patients Prescribed Long-term Opioid Therapy, 2008-2017
Fenton, J. J., Agnoli, A. L., Xing, G., Hang, L., Altan, A. E., Tancredi, D. J., Jerant, A., & Magnan, E. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.16271 · Cited by 97 · cited 3×
“…34.0% of the original dose per month and more than a quarter of patients were tapering at a rate faster than 40% of their original dose per month, 43,49 even higher than the maximum rate recommended by the CDC. 1 Another study in China had similar findings: with 50.4% of patients tapered faster…”
InfluentialLerner, A., & Klein, M. (2019) · Brain Communications · doi:10.1093/braincomms/fcz025 · Cited by 89 · cited 2×
“20,21 The pivotal importance of the MOR in the effect of opioids is borne out by studies that find that opioid agonist effects are linearly related to occupancy of this receptor.”
Nosyk, B., Sun, H., Evans, E., Marsh, D. C., Anglin, M. D., Hser, Y., & Anis, A. H. (2012) · Addiction · doi:10.1111/j.1360-0443.2012.03870.x · Cited by 81 · cited 7×
“33 These reductions should continue until patients reach a dose from which a reduction to zero does not cause a greater reduction in MOR occupancy than previously tolerated reductions.”
InfluentialMelichar, J. K., Hume, S. P., Williams, T. M., Daglish, M. R. C., Taylor, L. G., Ahmad, R., Malizia, A. L., Brooks, D. J., Myles, J. S., Lingford-Hughes, A., et al. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.072686 · Cited by 71 · cited 2×
“38,39 This has been attributed to either the insensitivity of the radi-otracers used, or to their inability to label receptors internalised by methadone agonism.”
Ralphs, J. A., de C Williams, A. C., Richardson, P. H., Pither, C. E., & Nicholas, M. K. (1994) · Pain · doi:10.1016/0304-3959(94)90166-x · Cited by 70 · cited 2×
“56 Given the limitations in these studies, further research in this area may be required to determine the role of blind tapers.”
Dunn, K. E., Sigmon, S. C., Strain, E. C., Heil, S. H., & Higgins, S. T. (2011) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.05.033 · Cited by 65
Avery, N., McNeilage, A. G., Stanaway, F., Ashton-James, C. E., Blyth, F. M., Martin, R., Gholamrezaei, A., & Glare, P. (2022) · BMJ · doi:10.1136/bmj-2021-066375 · Cited by 56
Slow tapering from methadone maintenance in a program encouraging indefinite maintenance
Calsyn, D. A., Malcy, J. A., & Saxon, A. J. (2006) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2005.11.007 · Cited by 55 · cited 2×
“6,7,33 One study examining almost 15,000 patients on opioid maintenance treatment for opioid dependence attempting a taper found that only 4.4% of patients were able to stop altogether or to reduce their opioids to a low dose ( 5 mg/day of methadone).”
InfluentialJones, A. K., Ngaimisi, E., Gopalakrishnan, M., Young, M. A., & Laffont, C. M. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00957-0 · Cited by 53 · cited 1×
“66 Sequential lowering of the doses of these long-acting formulations or extending the dosing interval 67 might provide a smoother transition in tapering dose, making the process more tolerable.”
Groot, P. C., & van Os, J. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320932452 · Cited by 49 · cited 1×
“63,64 Manufacturers might facilitate this process by producing smaller dose drug formulations.”
Tapering antipsychotic treatment
Horowitz, M. A., Murray, R. M., & Taylor, D. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.2166 · Cited by 49
Self-citationBlackman, G., Oloyede, E., Horowitz, M., Harland, R., Taylor, D., MacCabe, J., & McGuire, P. (2022) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab103 · Cited by 48
Self-citationStrang, J., & Gossop, M. (1990) · Addictive Behaviors · doi:10.1016/0306-4603(90)90054-2 · Cited by 42 · cited 1×
“15 In fact, some existing guidelines do recommend similar patterns of tapering.”
Self-citationPharmacodynamic principles and the time course of delayed and cumulative drug effects
Holford, N. (2018) · Translational and Clinical Pharmacology · doi:10.12793/tcp.2018.26.2.56 · Cited by 35 · cited 5×
“32 From this data, it can be seen that the recommended linear reductions of dose can be seen to give rise to increasingly large reductions in MOR activity (Figure 2(a)).”
InfluentialLintzeris, N., Monds, L. A., Rivas, C., Leung, S., Dunlop, A., Newcombe, D., Walters, C., Galea, S., White, N., Montebello, M., et al. (2018) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000396 · Cited by 34 · cited 1×
“37 Unfortunately, imaging of the relationship between methadone and opioid receptors has been difficult with two studies finding no relationship between dose and occupancy of opioid receptors.”
Tapering opioids: a comprehensive qualitative review
Davis, M. P., Digwood, G., Mehta, Z., & McPherson, M. L. (2020) · Annals of Palliative Medicine · doi:10.21037/apm.2019.12.10 · Cited by 33 · cited 2×
“58 The patients most likely to have a reduction in pain severity are those with mild to moderate pain.”
Factors associated with opioid-tapering success: A mixed methods study
Kuntz, J. L., Dickerson, J. F., Schneider, J. L., Firemark, A. J., Papajorgji-Taylor, D., Slaughter, M., Reese, K. R., Thorsness, L. A., Sullivan, M. D., Debar, L. L., et al. (2021) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2020.12.019 · Cited by 33 · cited 1×
“54 Lastly, expectancy effects have been shown to play a role in tapering.”
Characterization of methadone as a β-arrestin-biased μ-opioid receptor agonist
Doi, S., Mori, T., Uzawa, N., Arima, T., Takahashi, T., Uchida, M., Yawata, A., Narita, M., Uezono, Y., Suzuki, T., et al. (2016) · Molecular Pain · doi:10.1177/1744806916654146 · Cited by 31 · cited 2×
“…from PET imaging of MOR ) The relationship between dose of methadone in mice and its anti-nociceptive effect is hyperbolic, derived from data in Doi et al. 41 (b) The relationship between in vitro concentration of methadone and proportion of MOR binding (measured by displacement of…”
Read, J., Moncrieff, J., & Horowitz, M. A. (2023) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2023.03.013 · Cited by 30 · cited 1×
“31 While the relationship between occupancy and subjective effect is linear, the relationship between dose of opioid and occupancy of the MOR is hyperbolic, as exemplified by the partial agonist, buprenorphine (Figure 2).”
Self-citationThe Maudsley Deprescribing Guidelines – Antidepressants, Benzodiazepines, Gabapentinoids and Z‐drugs
(2024) · Wiley eBooks · doi:10.1002/9781394291052 · Cited by 27
How to reduce and stop psychiatric medication
Horowitz, M. A., & Taylor, D. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.10.001 · Cited by 26 · cited 2×
“25 An analogy could be made to descending a stair well: in the same way as it will cause less impact on the knees to jump down one stair a day as compared with jumping down 30 stairs in one go and then waiting 30 days before repeating the process, smaller reductions of dose made more often are…”
Self-citationWeinstein, Z. M., Gryczynski, G., Cheng, D. M., Quinn, E., Hui, D., Kim, H. W., Labelle, C., & Samet, J. H. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.05.010 · Cited by 23 · cited 1×
“6,7,33 One study examining almost 15,000 patients on opioid maintenance treatment for opioid dependence attempting a taper found that only 4.4% of patients were able to stop altogether or to reduce their opioids to a low dose ( 5 mg/day of methadone).”
InfluentialCooper, R. E., Ashman, M., Lomani, J., Moncrieff, J., Guy, A., Davies, J., Morant, N., & Horowitz, M. (2023) · PLOS ONE · doi:10.1371/journal.pone.0282988 · Cited by 23
Self-citationDarnall, B. D., & Fields, H. L. (2021) · Pain · doi:10.1097/j.pain.0000000000002443 · Cited by 20 · cited 1×
“57 For patients prescribed opioids for pain, it is important to inform them that generally speaking tapering off opioids does not increase pain and, in fact, may lead to a reduction in pain intensity over time: 80% of such patients show a reduction in pain, 15% have no change to their pain and only…”
Opioid tapering in patients with prescription opioid use disorder: A retrospective study
Zhou, K., Jia, P., Bhargava, S., Zhang, Y., Reza, T., Peng, Y. B., & Wang, G. G. (2017) · Scandinavian Journal of Pain · doi:10.1016/j.sjpain.2017.09.005 · Cited by 18 · cited 1×
“The use of other medications during tapering has been associated with successful cessation, 59 including various antidepressants, antipsychotics, gabapentin and pregabalin.”
Wallis, K. A., Donald, M., Horowitz, M. A., Moncrieff, J., Ware, R. S., Byrnes, J., Thrift, K., Cleetus, M., Panahi, I., Zwar, N. A., et al. (2023) · Trials · doi:10.1186/s13063-023-07646-w · Cited by 18
Self-citationRelative Potency of levo-α-Acetylmethadol and Methadone in Humans under Acute Dosing Conditions
Eissenberg, T., Stitzer, M. L., Bigelow, G. E., Buchhalter, A. R., & Walsh, S. L. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38221-7 · Cited by 14 · cited 3×
“…Doi et al. 41 (c) The relationship between oral dose of methadone and reduction in pupil size compared with placebo in humans, derived from data in Eissenberg et al. 40 (d) The relationship between oral dose of methadone and reported drug effect (‘Do you feel any drug effect?’) in humans, derived…”
InfluentialLu, Q., Zou, X., Liu, Y., Gong, C., & Ling, L. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16152800 · Cited by 13 · cited 2×
“45 A vitally important aspect to consider is the experience of the individual patient.”
O’Neill, J. R., Taylor, D. M., & Horowitz, M. A. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231198463 · Cited by 12 · cited 2×
“68 There are pros and cons to such an approach: relative simplicity on the one hand, but also a lack of control for the patient, with difficulty varying the rate of decrease (such as can be achieved with shorter acting oral medications) recognised to be a helpful element in the discontinuation…”
Self-citationComparison of three outpatient methadone detoxification procedures.: (470982004-001)
Stitzer, M. L., Bigelow, G. E., & Liebson, I. A. (1982) · PsycEXTRA Dataset · doi:10.1037/e470982004-001 · Cited by 8
O’Neill, J. R., Taylor, D. M., & Horowitz, M. A. (2024) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253241272790 · Cited by 7 · cited 2×
“69 Another option may be presented by use of the very long-acting buprenorphine implant (Sixmo), 70 which exhibits flip-flop pharmacokinetics (where the absorption half-life predominates over the elimination half-life to determine duration of drug action) 71 and might allow gradual tapering by…”
Self-citationSteinman, M. A. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.2965 · Cited by 4
Tackling rising numbers of opioid prescriptions users
Groot, P. C., & van Os, J. (2020) · The Lancet Public Health · doi:10.1016/s2468-2667(19)30247-6 · Cited by 4 · cited 1×
“63,64 Manufacturers might facilitate this process by producing smaller dose drug formulations.”
Kumar, R., Viswanath, O., & Saadabadi, A. (2024) · PubMed
Research works printed but not linked: 5
- National Institute for Health and Care Excellence. Opioid dependence. London, UK: National Institute for Health and Care Excellence, 2019.
- Lintzeris N, Clark N, Winstock A, et al. National clinical guidelines and procedures for the use of buprenorphine in the maintenance treatment of opioid dependence. Australian Government. 2006.
- Taylor D, Barnes T, Young A. The Maudsley prescribing guidelines in psychiatry: 13th Edition. Hoboken, NJ: Wiley Blackwell, 2018.
- Horowitz MA Taylor D. Case-based learning: safe withdrawal and tapering of antidepressants [Internet]. The Pharmaceutical Journal https://pharmaceutical-journal.com/article/ld/case-based-learning-safe-withdrawal-and-tapering-of-antidepressants (2023 accessed 6 October 2023).
- Center for Substance Abuse Treatment. Protracted withdrawal. Substance Abuse Treatment Advisory 2010; 9(1): 1–8.
Cited by
Fishman, M. J., Stoops, W. W., Podesta, A., Wyatt, S. A., DeVeaugh‐Geiss, A., Gray, F. A., & Moigne, A. L. (2026) · Drug and Alcohol Dependence Reports · doi:10.1016/j.dadr.2026.100471
“From a clinical perspective, this pharmacokinetic profile may reduce the need for the complex tapering schedules often required with daily formulations (Horowitz et al., 2025) and facilitate a more gradual physiologic transition following treatment discontinuation.”
Metadata
- Authors
- Abie Horowitz, M., Framer, A., Strang, J., & Taylor, D.
- Affiliations
- Department of Research and Development, North East London Foundation Trust, Goodmayes Hospital, 157 Barley Ln, Goodmayes, Ilford IG3 8XJ, UK
- Psychotropic Deprescribing Council, San Francisco, CA, USA
- King's College London (GB)
- Venue
- Therapeutic Advances in Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2025-10
- Volume
- 15
- Pages
- 20451253251371504-20451253251371504
- ISSN
- 2045-1253 (ISSN-L)
- 2045-1261
- PMC
- PMC12579163
- OpenAlex
- W4415732754
- Semantic Scholar
- 43fad25c9ca41219b1e975bc097f9449681f9470
- Cited by
- 0
- References
- 53
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0/ (vor)
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Therapeutic Advances in Psychopharmacology (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Pain Management
- Keywords
- opioid tapering, opioid withdrawal, dose tapering, mu-opioid receptor, pharmacodynamics, buprenorphine, methadone, opioid cessation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.